title: Pharmacotherapy: Quest for the quitting pill.
authors.forename: Cassandra
authors.initials: C
authors.lastname: Willyard
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology*; D002047:Buprenorphine / Q000627:therapeutic use; D000069479:Buprenorphine, Naloxone Drug Combination; D002986:Clinical Trials as Topic; D019970:Cocaine-Related Disorders / Q000188:drug therapy / Q000276:immunology / Q000523:psychology; D003376:Counseling; D004298:Dopamine / Q000378:metabolism; D055808:Drug Discovery / Q000191:economics; D004345:Drug Industry / Q000191:economics; D006801:Humans; D007050:Ibogaine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D008120:Lobeline / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009270:Naloxone / Q000627:therapeutic use; D009271:Naltrexone / Q000627:therapeutic use; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000276:immunology / Q000523:psychology; D057181:Pleasure / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D011978:Receptors, Nicotinic / Q000378:metabolism; D012201:Reward; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology*; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism
chemical_list: D000069479:Buprenorphine, Naloxone Drug Combination; D009842:Oligopeptides; D011978:Receptors, Nicotinic; C493452:SLC18A2 protein, human; D014612:Vaccines; D050493:Vesicular Monoamine Transport Proteins; C403530:nicotinic receptor alpha3beta4; D009270:Naloxone; D007050:Ibogaine; D002047:Buprenorphine; D009271:Naltrexone; D008120:Lobeline; C525167:larazotide acetate; C103345:18-methoxycoronaridine; D004298:Dopamine